Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.76 |
| ▸ | PLAU | P00749 | 8/20 | 0.76 |
| ▸ | PLAT | P00750 | 2/20 | 0.68 |
| ▸ | PLG | P00747 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | PARP1 | P09874 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22223646 | 0.89 | PTPN1 (0.76) | PTPN1PLAUPLATPLGRAB9A | |
| SCHEMBL8745242 | 0.88 | PTPN1 (0.77) | PTPN1PLAURAB9AKMT2APOLB | |
| SCHEMBL677703 | 0.87 | RAB9A (0.86) | PTPN1PLAURAB9AMEN1KMT2A | |
| SCHEMBL2835618 | 0.87 | PTPN1 (0.94) | PTPN1PLAURAB9AMEN1KMT2A | |
| SCHEMBL22223650 | 0.87 | PTPN1 (0.94) | PTPN1PLAURAB9AMEN1KMT2A | |
| SCHEMBL29611669 | 0.87 | PTPN1 (0.94) | PTPN1PLAURAB9AMEN1KMT2A | |
| SCHEMBL2025738 | 0.87 | NR1H4 (0.72) | PTPN1RAB9AMEN1KMT2APOLB | |
| SCHEMBL5943892 | 0.85 | MEN1 (0.71) | PTPN1PLAURAB9AMEN1KMT2A | |
| SCHEMBL27760395 | 0.85 | PTPN1 (0.76) | PTPN1PLAURAB9AMEN1KMT2A | |
| SCHEMBL13601057 | 0.85 | HDAC8 (0.71) | PTPN1RAB9AMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | PTPN1 4475/4885PLAU 2273/4885PLAT 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.